The Need for Steatotic Liver Disease and MASH Research
Steatotic liver disease (formerly known as fatty liver disease) is a condition characterized by the accumulation of fat in the liver. It can be caused by excessive alcohol consumption (MetALD) or by factors unrelated to alcohol (metabolic dysfunction-associated steatotic liver disease or MASLD). MASLD encompasses a range of conditions, with the most severe form known as metabolic dysfunction-associated steatohepatitis (MASH). MASH is a progressive liver disease that can lead to liver fibrosis, cirrhosis, and even liver cancer.
Currently, there is no approved medication specifically for the treatment of MASH. The standard recommendations for managing steatotic liver disease and MASH involve lifestyle modifications. These include weight loss through a healthy diet and regular exercise, as well as the management of associated conditions such as diabetes, high blood pressure, and high cholesterol.
Research efforts have been focused on developing pharmacological treatments to target the underlying mechanisms of MASH and reduce liver fat accumulation, inflammation, and fibrosis. Several clinical trials are underway to evaluate the safety and efficacy of various investigational drugs.
How to Participate in a Steatotic Liver Disease Clinical Trial
Velocity has research sites nationwide that are conducting clinical trials in a wide range of therapeutic areas. New studies are added every week. You can help advance MASH research by joining a clinical trial at Velocity.
Beyond helping advance medicine, you may also:
- Learn about potential new medicines in development
- Get study-related medical exams at no cost
- Receive compensation for participating (available amounts may differ for each study)
The best way to find out which research studies are currently enrolling patients in your community and determine your eligibility is to complete the form on this page or call Velocity to speak with an enrollment specialist.
After you submit your information, a Velocity enrollment specialist will contact you. Together, we’ll review studies that might be right for you and answer your questions.
Health insurance is NOT required to join. There is never an obligation to participate — we’re here to help you make the best decision.
For more information about currently enrolling clinical trials, complete the form on this page or select a location below to get in touch with a Velocity enrollment specialist.
Note
All instances of “NASH,” “fatty liver disease,” and “MASLD” have been updated to “MASH,” “steatotic liver disease,” and “MASLD” respectively since the original publishing of this page due to nomenclature updates.
